Encontrados 6 documentos, a visualizar página 1 de 1
Sitagliptin treatment prevented pancreatic lesions evolution in a rat modelo f ...
Mega, C.; Vala, Helena; Oliveira, J.; Teixeira, F.; Fernandes, R.; Teixeira-Lemos, E.; Reis, F.Background: This study aimed to elucidate mechanisms underlying the protective effects of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, against pancreatic lesions, in an animal model of T2DM. Methods: Male obese diabetic ZDF (fa/fa) rats, 20-weeks-old, were treated with vehicle or sitagliptin (10mg/kg BW/day) for 6 weeks, and compared with lean control littermates (n=8/each). Biochemical parameters ...
Erythropoietin doping as cause of sudden death in athletes: an experimental study
Piloto, N.; Teixeira, H.M.; Teixeira-Lemos, E.; Parada, B.; Garrido, P.; Sereno, J.; F. Pinto, A.F.; Costa, Elísio; Belo, L.; Santos-Silva, A.Aims: To evaluate the cardiovascular (CV) effects of rhEPO treatment in rats under chronic aerobic exercise and to assess the probable cause of sudden death in one rat. Protocol: Male Wistar rats: control - sedentary; rhEPO - 50 IU/Kg/3xwk; swimming (EX) -1 hr, 3x/wk; EX+EPO. Hematology, catecholamines and serotonin, redox status and inflammation, were assessed. One rat of EX+EPO group suffered a sudden death e...
Hemorheological and cardiovascular effects of erythropoietin in a rat model of ...
Piloto, N.; Teixeira, HM; Garrido, P.; Teixeira-Lemos, E.; Teixeira, M.; Parada, B.; Sereno, J.; Pinto, R .; Alves, R.; Santos, P.; Romão, AM; Nunes, S.Recombinant human erythropoietin (rhEPO) has been therapeutically used for correction of anaemia. However, due to the increase in circulating red blood cells (RBCs) it promotes, thus increasing oxygen delivery to muscles and improving performance in sport, it has been also illegally used as sports doping. Besides the well known increase of hematocrit and blood viscosity; which might cause serious complications ...
Caracterização hemorreológica, bioquímica e cardiovascular num modelo de doença...
Garrido, P.; Costa, Elísio; Teixeira-Lemos, E.; Parada, B.; Teixeira, M.; Santos, P.; Piloto, N.; Sereno, J.; Alves, R.; Pinto, R.; Rocha-Pereira, P.Chronic kidney disease (CKD) is a major public health problem throughout the world. The major outcomes include a rapid progression, with development of anaemia and serious complications, namely thromboembol ic and cardiovascular events. The pathophysiological alterations depend on the CKD degree, which will also determine the moment to initiate hemodialysis and recombinant erythropoietin (rhEPO) therapies Thus,...
Effect of recombinant human erythropoietin in a rat model of moderate chronic r...
Garrido, P.; Reis, Flávio; Costa, Elísio; Almeida, A.; Parada, B.; Teixeira-Lemos, E.; Santos, P.; Alves, R.; Sereno, J.; Pinto, R.; Tavares, C. A.Background/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency degree might determine the moment to start recombinant human EPO (rhEPO) therapy. It has been attributed important non-hematopoietic effects to rhEPO, which might underlie cardio and renoprotectio...
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyc...
Parada, B; Sereno, J; Reis, F; Teixeira-Lemos, E; Garrido, P; Pinto, AF; Xavier da Cunha, MF; Pinto, R; Mota, A; Figueiredo, A; Teixeira, FPURPOSE: To evaluate the efficacy of a selective cyclooxygenase-2 (COX-2) inhibitor in rat bladder cancer chemoprevention, as well as to assess the relevance of inflammation, proliferation and oxidative stress in tumor growth and in its prevention. RESULTS: The main findings were: (I) the incidence of carcinoma was: control: 0% (0/8); BBN: 65% (13/20); CEL: 0% (0/8) and BBN + CEL: 12.5% (1/8); (II) the mean tu...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||